Rentschler Biopharma SE and Leukocare AG have reported on the successful first year of their strategic alliance. The collaboration incorporates best-in-class formulation development in every step of the biopharmaceutical development and manufacturing process. The benefits of this combination include competitive advantages, shorter development timelines, cost savings and extra patent protection for client products. In the past year, the alliance has won several new client projects, including four with U.S.-based companies.

Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma's biopharmaceutical development business. Rentschler Biopharma is the first and only CDMO to have access to Leukocare's patented SPS(R) formulation technologies. As part of the original agreement, Rentschler Biopharma holds a 10% stake in Leukocare and Frank Mathias, chief executive officer, Rentschler Biopharma SE, is a member of Leukocare's board of directors.

"The first year of this strategic alliance between Rentschler Biopharma and Leukocare was a great success and has proven our rationale to deliver best-in-class formulation throughout the biopharmaceutical value chain," said Dr. Mathias. "By repositioning formulation as a key success factor in biopharmaceutical development, we have initiated vital discussions throughout the industry. Both existing and new clients have responded very positively to this new strategy."

Michael Scholl, chief executive officer, Leukocare AG, said, "Over the past year, our alliance has received a great deal of interest and recognition for this striking approach. We have been able to expand our client base, particularly in the U.S., and look forward to acquiring further clients and development projects in the near term. This innovative approach provides our current and future clients significant competitive advantages, enabling them to exploit the full potential of their products and markets."